Dynamic42 raises mid-seven-figure in Series A financing round

13 Jun 2023

Dynamic42 raises mid-seven-figure in Series A financing round

Jena-based start-up Dynamic42 GmbH ­– an innovative organ-on-chip specialist – has raised a mid-seven-figure investment in a Series A financing round. The funding, led by existing lead investor bm-t beteiligungsmanagement thüringen gmbh (bm-t) and a family office from the health sector, will be used to support the company's growth, development and vision over the coming years.

Founded in March 2018, Dynamic42 is a spin-off from the Integrated Research and Treatment Center for Sepsis Control and Care (CSCC) of the University Hospital Jena. It offers its customers miniaturized human organ models (so-called organ-on-chip) for drug testing.

The decisive factor for the investment was above all the added value that the use of the technology generates for society. This includes increased drug safety, reduced drug development costs and a reduction in animal testing.

Dynamic42's technology offers a very good alternative to existing systems in drug development and has high market potential. We can proudly announce that we have created an up-and-coming company and are extremely pleased about this strategically important investment. In times of a more challenging investment market, it is a strong signal for us that our technology and vision possess high potential,” said Managing Directors Dr Martin Raasch and Dr Knut Rennert.

The company's new chip enables the cultivation of three-dimensional tissue cultures. “The chip allows us to dive into completely new application areas for organ-on-chip technology, such as cancer research,” explains Dr. Martin Raasch, CEO of Dynamic42.

With the investment, Dynamic42 will continue the further development of products and services, open new markets, recruit highly qualified personnel, further develop the company infrastructure and expand the property rights portfolio and sales infrastructure. An important milestone in the coming years will be the internationalization of the company, including entry into the USA as the world's largest pharmaceutical market.